

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HUANG et al.

Continuation of Appln. No. 10/270,313

Confirmation No. Not Yet Assigned

Filed: December 16, 2003

For: METHOD FOR TREATMENT OF
TUMORS USING
NORDIHYDROGUAIARETIC
ACID DERIVATIVES

Art Unit: 1614

Examiner: James H. Reamer

Atty. Docket No.: 2240-199065

Customer No.:

26694

Information Disclosure Statement


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents that are listed on the attached PTO-1449 forms. All of the listed references are of record in parent Application No. 10/270,313 where copies may be obtained in accordance with customary PTO practice. Applicants request that these documents be considered and listed on the face of any patent granted in this application.

Respectfully submitted,

Date: 12/16/03



Ann S. Hobbs, Ph.D.

Registration No. 36,830

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000

Telefax: (202) 344-8300

#509191v1



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

of	2
----	---

Application Number

Complete if Known

Continuation of Appln. 10/270,313

Filing Date

December 16, 2003

First Named Inventor

Ru Chih C. HUANG et al.

Group Art Unit

1614

Examiner Name _____

Mr. James H. Reamer

Attorney Docket Number

2240-199065

sU.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	6,365,787		Huang et al.	04/2002	
	2	5,663,209		Huang et al.	09/1997	
	3	6,291,524		Huang et al.	09/2001	
	4	6,214,874		Huang et al.	04/2001	
	5	4,774,229		Jordan	09/1988	
	6	5,276,060		Neiss et al.	01/1994	
	7	6,071,949		Mulshine et al.	06/2000	
	8	4,425,327		Moller et al.	01/1984	
	9	4,880,637		Jordan	11/1989	
	10	5,008,294		Neiss et al.	04/1991	
	11	5,559,149		Clum et al.	09/1996	
	12	5,827,898		Khandwala et al.	10/1998	
	13	5,837,252		Sinnott et al.	11/1998	
	14	5,965,616		Wang et al.	10/1999	
	15	6,165,788		Bennett et al.	12/2000	
	16	6,245,523		Altieri	01/2001	

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT****Complete if Known**

Application Number	Continuation of Appln. 10/270,313
Filing Date	December 16, 2003
First Named Inventor	Ru Chih C. HUANG et al.
Group Art Unit	1614
Examiner Name	Mr. James H. Reamer

(use as many sheets as necessary)

Sheet	2	Of	2	Attorney Docket Number	2240-199065
-------	---	----	---	------------------------	-------------

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	17	Russell et al.; "Neoplasm inhibitors comprising metal salts and phenol derivatives"; CA: 111(3)17704R PATENT ABSTRACT	
	18	Rao et al.; "Regioselective cleavage of the methylenedioxy group: conversion of (-)-austrobaillignan-5 to (-)-dihydroguaiaretic acid"; CA: 112(23)118499d JOURNAL ABSTRACT	
	19	Giza et al., "A self-inducing runaway---replication plasmid expression system utilizing the ROP protein," Gene 78:73-84 (1989).	
	20	Gnabre et al., "Isolation of anti-HIV-1 lignans from <i>Larrea tridentate</i> counter-current chromatography," J. Chromatography A, 719: 353-364 (1995).	
	21	C.W. Perry et al., "Synthesis of Lignans. I. Nordihydroguaiaretic Acid"; J. Org. Chem. 37(26): 4371-4376 (1972).	
	22	Staal et al., "Antioxidants inhibit stimulation of HIV transcription," AIDS Research and Human Retroviruses, 9(4): 299-306 (1993).	
	23	Weislow et al., "New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS---Antiviral activity," J. National Cancer Inst. 81(1): 577-586 (1989).	
	24	Russell; "Compositions containing catecholic butanes and zinc for treating solid tumors"; CA: 110(12)101816r PATENT ABSTRACT	
	25	Chen et al., Antiviral Activities of Methylated Nordihydroguaiaretic Acids 2. Targeting Herpes Simplex Virus Replication by Mutation Insensitive Transcription Inhibitor Tetra-O-methyl-NDGA, Journal of Medicinal Chemistry, 1998, Vol. 41, No. 16, pp.301-3007	
	26	Gnabre et al., Characterization of Anti-HIV Lignans from <i>Larrea Tridentata</i> , Tetrahedron 1995, Vol. 51, No. 45, pp. 12203-12210	
	27	Gnabre et al, Inhibition of Human Immunodeficiency Virus Type 1 Transcription and Replication by DNA Sequence-S-elective Plant Lignans, Proc. Natl. Acad. Sci., USA, 1995, Vol. 92, pp. 11239-11243	
	28	Gisvold et al., Lignans from <i>Larrea Divaricata</i> , Journal of Pharmaceutical Sciences, 1994, Vol. 63, No. 12, pp. 1905-1907	
	29	Hwu et al, Antiviral Activities of Methylated Nordihydroguaiaretic Acids. 1. Synthesis Structure Identification and Inhibition of Tat-Regulated HIV Transactivation J. Med. Chem., 1998, Vol. 41, No. 16, pp. 2994-3000	
	30	Huang et al., Regulation of HIV Promotor Activities in Human Embryonal Carcinoma Cells, NTERA-2, Gene Regulation and AIDS, 1989, pp. 147-160	
	31	Li et al., Transcriptional Analysis of Human Survivin Gene Expression, Biochem. J. (1999), 344 pp. 305-311.	
	32	Connor et al., Regulation of Apoptosis Cell Division by p34cdc2 Phosphorylation of Survivin, PNAS, Nov. 21, 2000, Vol. 27, No. 24, pp. 13101-13107	
	33	Li et al., The Cancer Antiapoptosis Mouse Survivin Gene: Characterization of Locus and Transcriptional Requirements of Basal and Cell Cycle-Dependent Expression, Cancer Research 59, July 1, 1999, pp. 3134-3151	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.